RT Journal Article SR Electronic T1 The Novel CA IX Inhibition Antibody chKM4927 Shows Anti-tumor Efficacy In Vivo JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 1997 OP 2004 VO 35 IS 4 A1 AYAMI YAMAGUCHI A1 KATSUAKI USAMI A1 MUNETAKE SHIMABE A1 KAZUMASA HASEGAWA A1 MASAO ASADA A1 KAZUHIRO MOTOKI A1 TOMOYUKI TAHARA A1 KAZUHIRO MASUDA YR 2015 UL http://ar.iiarjournals.org/content/35/4/1997.abstract AB Carbonic anhydrase IX (CA IX) is an attractive target for cancer therapy. Many anti-CA IX antibodies have been reported but few have been shown to possess inhibition activity. Furthermore, effective use of CA IX-inhibition antibodies for cancer immunotherapy has not been well-validated since data are mainly limited to in vitro assays. In this study, we established that chKM4927, an anti-CA IX chimeric antibody, recognizes CA IX and has CA IX-specific inhibition activity. ChKM4927 also retains antibody-dependent cellular cytotoxicity (ADCC) activity against CA IX-expressing cancer cells. Compared to controls, chKM4927 treatment (10 mg/kg) showed anti-tumor activity in the VMRC-RCW xenograft model in vivo. ChKM4927-attenuated ADCC activity showed equally effective anti-tumor activity. These results suggest that the CA IX-inhibition antibody chKM4927 has an anti-tumor effect in the VMRC-RCW xenograft model via an ADCC-independent mechanism.